Frontiers in Oncology (Jun 2024)

Cardio-oncology in advanced prostate cancer

  • Kenneth Chen,
  • Kenneth Chen,
  • Ting Hong Wong,
  • Yu Guang Tan,
  • Kae Jack Tay,
  • Kae Jack Tay,
  • Wei Chong Tan,
  • Johan Chan,
  • Henry Ho,
  • Christopher Cheng,
  • Jeremy Yuen-Chun Teoh,
  • Peter Ka-Fung Chiu,
  • Hung Jen Wang,
  • Marniza Binti Saad,
  • Ravindran Kanesvaran,
  • You Quan Li,
  • Choon Ta Ng,
  • Jeffrey Kit Loong Tuan,
  • John Shyi Peng Yuen,
  • John Shyi Peng Yuen

DOI
https://doi.org/10.3389/fonc.2024.1386597
Journal volume & issue
Vol. 14

Abstract

Read online

Treatment intensification with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPi) have led to improved survival in advanced prostate cancer. However, ADT is linked to significant cardiovascular toxicity, and ARPi also negatively impacts cardiovascular health. Together with a higher prevalence of baseline cardiovascular risk factors reported among prostate cancer survivors at diagnosis, there is a pressing need to prioritise and optimise cardiovascular health in this population. Firstly, While no dedicated cardiovascular toxicity risk calculators are available, other tools such as SCORE2 can be used for baseline cardiovascular risk assessment. Next, selected patients on combination therapy may benefit from de-escalation of ADT to minimise its toxicities while maintaining cancer control. These patients can be characterised by an exceptional PSA response to hormonal treatment, favourable disease characteristics and competing comorbidities that warrant a less aggressive treatment regime. In addition, emerging molecular and genomic biomarkers hold the potential to identify patients who are suited for a de-escalated treatment approach either with ADT or with ARPi. One such biomarker is AR-V7 splice variant that predicts resistance to ARPi. Lastly, optimization of modifiable cardiovascular risk factors for patients through a coherent framework (ABCDE) and exercise therapy is equally important. This article aims to comprehensively review the cardiovascular impact of hormonal manipulation in metastatic hormone-sensitive prostate cancer, propose overarching strategies to mitigate cardiovascular toxicity associated with hormonal treatment, and, most importantly, raise awareness about the detrimental cardiovascular effects inherent in our current management strategies involving hormonal agents.

Keywords